Search

Displaying results 1781 - 1790 of 10000 in total
  1. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    compared to standard VRd therapy. … In July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients.

  2. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.

    Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  3. Target

    Light-harvesting protein B-800/820 alpha chain

    go.drugbank.com/bio_entities/BE0003921
    TargetRhodopseudomonas acidophila

    Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.

    Synonyms: LH3 complex subunit alpha
  4. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system. … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.

  5. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    two apheresis procedures, compared to ~26% of patients receiving only filgrastim. … [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple

  6. Drug

    Edetic acid

    go.drugbank.com/drugs/DB00974
    ApprovedInvestigationalVet approved

    It is used in pharmaceutical manufacturing and as a food additive.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
  7. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia.

  8. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It gained approval by European Commission in March 2009. … Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.

  9. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … a 68% reduction in the risk of death were observed.

  10. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.